These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Nölting S; Grossman AB Endocr Pathol; 2012 Mar; 23(1):21-33. PubMed ID: 22391976 [TBL] [Abstract][Full Text] [Related]
3. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs). Khatami F; Mohammadamoli M; Tavangar SM Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919 [TBL] [Abstract][Full Text] [Related]
4. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies. Santarpia L; Habra MA; Jiménez C Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618 [TBL] [Abstract][Full Text] [Related]
5. Genetics of pheochromocytomas and paragangliomas. Opocher G; Schiavi F Best Pract Res Clin Endocrinol Metab; 2010 Dec; 24(6):943-56. PubMed ID: 21115163 [TBL] [Abstract][Full Text] [Related]
6. Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. Yao L; Schiavi F; Cascon A; Qin Y; Inglada-Pérez L; King EE; Toledo RA; Ercolino T; Rapizzi E; Ricketts CJ; Mori L; Giacchè M; Mendola A; Taschin E; Boaretto F; Loli P; Iacobone M; Rossi GP; Biondi B; Lima-Junior JV; Kater CE; Bex M; Vikkula M; Grossman AB; Gruber SB; Barontini M; Persu A; Castellano M; Toledo SP; Maher ER; Mannelli M; Opocher G; Robledo M; Dahia PL JAMA; 2010 Dec; 304(23):2611-9. PubMed ID: 21156949 [TBL] [Abstract][Full Text] [Related]
7. [Pheochromocytomas and paragangliomas: implications of new insights for diagnosis and treatment]. van der Kleij-Corssmit EP; Havekes B; Vriends AH; Jansen JC; Romijn JA Ned Tijdschr Geneeskd; 2008 Mar; 152(9):489-93. PubMed ID: 18389879 [TBL] [Abstract][Full Text] [Related]
8. Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Favier J; Meatchi T; Robidel E; Badoual C; Sibony M; Nguyen AT; Gimenez-Roqueplo AP; Burnichon N Mod Pathol; 2020 Jan; 33(1):57-64. PubMed ID: 31383958 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations. Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394 [TBL] [Abstract][Full Text] [Related]
10. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors. Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588 [TBL] [Abstract][Full Text] [Related]
11. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era. Pillai S; Gopalan V; Smith RA; Lam AK Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173 [TBL] [Abstract][Full Text] [Related]
13. Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas. Torresan F; Iacobone C; Giorgino F; Iacobone M Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000254 [TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of pheochromocytomas and paragangliomas. McNichol AM Endocr Pathol; 2001; 12(4):407-15. PubMed ID: 11914474 [TBL] [Abstract][Full Text] [Related]
15. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry. Juhlin CC Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452 [TBL] [Abstract][Full Text] [Related]
16. The VHL gene is epigenetically inactivated in pheochromocytomas and abdominal paragangliomas. Andreasson A; Kiss NB; Caramuta S; Sulaiman L; Svahn F; Bäckdahl M; Höög A; Juhlin CC; Larsson C Epigenetics; 2013 Dec; 8(12):1347-54. PubMed ID: 24149047 [TBL] [Abstract][Full Text] [Related]
17. Novel hereditary forms of pheochromocytomas and paragangliomas. Dahia PL Front Horm Res; 2013; 41():79-91. PubMed ID: 23652672 [TBL] [Abstract][Full Text] [Related]
18. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246 [TBL] [Abstract][Full Text] [Related]
19. Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Favier J; Igaz P; Burnichon N; Amar L; Libé R; Badoual C; Tissier F; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP Endocr Pathol; 2012 Mar; 23(1):34-42. PubMed ID: 22183643 [TBL] [Abstract][Full Text] [Related]